Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20384645 | 0.93 | GNAI3 (0.41) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL26375600 | 0.91 | LMNA (0.43) | GNAI3GNAO1GNAI1TP53SMN1; SMN2 | |
| SCHEMBL23841915 | 0.89 | GNAI3 (0.52) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL1810789 | 0.89 | HRH3 (0.46) | GNAI3GNAO1GNAI1TP53SMN1; SMN2 | |
| SCHEMBL27057345 | 0.89 | GBA1 (0.43) | GNAI3GNAO1GNAI1TP53SMN1; SMN2 | |
| SCHEMBL19861351 | 0.87 | GNAI3 (0.39) | GNAI3GNAO1GNAI1KDM4ETP53 | |
| SCHEMBL26504295 | 0.87 | GNAI3 (0.53) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL21016406 | 0.85 | GNAI3 (0.42) | GNAI3GNAO1GNAI1KDM4ETP53 | |
| SCHEMBL21016199 | 0.85 | GNAI3 (0.42) | GNAI3GNAO1GNAI1KDM4ETP53 | |
| SCHEMBL105381 | 0.84 | PAOX (0.47) | GNAI3GNAO1GNAI1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021127278-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.